Entity

Time filter

Source Type

Trophos is a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.Trophos was founded in 1999 in Marseille by three scientists, Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus and two entrepreneurs, Antoine Beret and Michel Delaage. Trophos' lead compound is TRO19622 / olesoxime,.. Olesoxime is a mitochondrial targeted compound, which will be established as first of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases. Spinal Muscular Atrophy is an autosomal recessive genetic disease that affects the motor neurons of the voluntary muscles used for activities such as crawling, walking, head and neck control and swallowing. SMA affects approximately 20,000 people worldwide. One in every 6,000 babies is born with SMA. It is the number one genetic cause of death in children under the age of two. Results from an international, double-blind, placebo-controlled phase II study involving 165 type II and non-ambulatory type III SMA patients, completed in February 2014 to assess safety and efficacy of olesoxime were recently released. The data shows that patients treated with olesoxime were able to maintain motor function over the two-year period of the study and that typical health complications associated with SMA occurred less frequently than in patients treated with a placebo, leading to better well being.In January 2015, the firm was acquired by Hoffmann-La Roche. Wikipedia.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2009-2.4.4-1 | Award Amount: 8.05M | Year: 2010

The Collaborative Project on Mendelian Forms of Parkinsons Disease (MEFOPA) will bring together the major groups in Europe with a track-record in basic and clinical research on rare Mendelian forms of Parkinsons disease (PD) in order to identify and validate relevant disease-related molecular pathways, drug-targets and biomarkers for disease susceptibility and progression.. Over the last years it has become increasingly clear that progress in the understanding of the molecular basis of PD, the second most common neurodegenerative disorder, and hence the chance to develop effective disease-modifying treatments, will most likely be brought about by focusing on the rare variants of the disease with known genetic defects. The groups forming the MEFOPA-consortium will therefore analyze the molecular pathways underlying inherited forms of PD with autosomal-dominant and autosomal-recessive inheritance in an integrative way, using cellular and animal models and cutting-edge technology. These two subprojects will provide targets for novel, disease-modifying treatment strategies. In a third subproject, a European registry and biobank for patients with rare Mendelian forms of PD will be established. Body fluids will be collected and systematically analyzed by unbiased proteomic techniques as well as by focussed analysis of candidate proteins, and ex vivo cellular models will be generated, in order to allow validation of disease-related alterations detected in the models analyzed in subprojects 1 and 2. Through this integrated, translational approach combining basic and clinical research groups, the project aims to achieve measurable progress in defining the relevant targets and readouts for disease-modifying therapies and will set the stage for rationally designed drug trials in carefully selected groups of patients and even presymptomatic mutation carriers.


A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an NOH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.


The present invention relates to a novel galenic form of cholesterol derivative. More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.


A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an NOH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.


Patent
Trophos | Date: 2012-08-22

A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an =NOH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.

Discover hidden collaborations